Skip to main content
. 2016 Jun 30;18(8):664–670. doi: 10.1016/j.hpb.2016.05.013

Table 2.

Patient characteristics in the intent-to-treat population

Rowachol (n = 71) Placebo (n = 67) P
Age in years 51.5 ± 15.6 48.0 ± 13.8 0.21
Gender (male: female) 26: 45 33: 34 0.13
BMI (kg/m2) 24.6 ± 3.7 25.2 ± 3.5 0.90
ASA class (minimal/moderate/severe) 46/25/0 43/24/0 0.94
Preoperative ERCP stone removal 8 (11.3) 6 (9.0) 0.65
GB stone 66 (93.0) 62 (92.5) 0.81
aCombined comorbid diseases 22 (31.2) 21 (31.3) 0.96
Single port cholecystectomy 5 (7.0) 7 (10.4) 0.48
Difficulty score in LC 0.5 ± 1.0 0.8 ± 1.2 0.54
bPostoperative complication 0 1 (1.5) 0.49
Open conversions 0 0 1.00
cPathology (acute: chronic) 6: 61 13: 53 0.17
Operative time (min) 51.9 ± 27.2 58.8 ± 30.0 0.14

Values denote mean values ± standard deviation or no. (%) of patients.

BMI indicates body mass index; ASA, American Society of Anesthesiologists; ERCP, Endoscopic Retrograde Cholangiopancreatography; LC, laparoscopic cholecystectomy.

a

Cardiovascular, Cerebrovascular, Diabetes mellitus, Chronic obstructive lung disease, Chronic renal failure, etc.

b

1 case of minor bile leak only, no other complication occurred.

c

3 cases xanthogranulomatous cholecystitis, 2 cases T1 GB cancer.